Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(Suppl 2):268-74
Article Links
Kawasaki Disease and COVID-19
Athanasios Gkoutzourelas1, Dimitrios P. Bogdanos1, Lazaros I. Sakkas1,2
Authors Information

1. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa

2. Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Athanasios Gkoutzourelas, Dimitrios P. Bogdanos, Lazaros I. Sakkas

Keywords: Atypical Kawasaki disease, Kawasaki-like disease, Kawasaki-COVID-19, paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, macrophage activation syndrome, myocarditis, toxic shock syndrome
References
  1. Kato H. Tribute to Dr. Tomisaku Kawasaki ― Discoverer of Kawasaki Disease and a Great Pediatrician. Circ J 2020;84(8):1209-11.
  2. Kawasaki T. Kawasaki disease. Int J Rheum Dis 2014;17(5):597-600.
  3. Kawasaki T, Singh S. Kawasaki disease - the journey over 50 years: 1967-2017. Int J Rheum Dis 2018;21(1):7-9.
  4. Daniels LB, Tjajadi MS, Walford HH, Jimenez-Fernandez S, Trofimenko V, Fick DB Jr, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation 2012;125(20):2447-53.
  5. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135(17):e927-e999.
  6. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis 2011;203(7):1021-30.
  7. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. Kawasaki disease in families. Pediatrics 1989;84(4):666-9.
  8. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol 2020;16(7):391-405.
  9. Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T, Sasazuki T. Genetic analysis of Kawasaki syndrome. Am J Hum Genet 1986;39(4):537-9.
  10. Kottek A, Shimizu C, Burns JC. Kawasaki disease in monozygotic twins. Pediatr Infect Dis J 2011;30(12):1114-6.
  11. Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 2005;141(3):381-7.
  12. Franco A, Touma R, Song Y, Shimizu C, Tremoulet AH, Kanegaye JT, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity 2014. 47(2):95-104.
  13. Franco A, Touma R, Song Y, Shimizu C, Tremoulet AH, Kanegaye JT, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One 2012;7(6):e38998.
  14. Yan X, Jin J, Su X, Yin X, Gao J, Wang X, et al. Intestinal Flora Modulates Blood Pressure by Regulating the Synthesis of Intestinal-Derived Corticosterone in High Salt-Induced Hypertension. Circ Res 2020;126(7):839-53.
  15. Eberhard BA, Sundel RP, Newburger JW, Baker A, Fuhlbrigge RC, Burns JC, et al. Psoriatic eruption in Kawasaki disease. J Pediatr 2000;137(4):578-80.
  16. Singh S, Jindal AK. Diagnosis of Kawasaki disease. Int J Rheum Dis 2018; 21(1):36-44.
  17. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991;118(5):680-6.
  18. Kim GB, Han JW, Park YW, Song MS, Hong YM, Cha SH, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011. Pediatr Infect Dis J;2014:33(1):24-7.
  19. Dionne A, Dahdah N. Myocarditis and Kawasaki disease. Int J Rheum Dis 2018;21(1):45-9.
  20. Piram M, Bello MD, Tellier S, Di Filippo S, Boralevi F, Madhi F, et al. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Sci Rep 2020;10(1):3125.
  21. Liu X, Zhou K, Hua Y, Wu M, Liu L, Shao S, et al. Neurological involvement in Kawasaki disease: a retrospective study. Pediatr Rheumatol Online J 2020;18(1):61.
  22. Javadi V, Shiari R. Mediastinal Lymphadenopathy in a Child with Kawasaki Disease. Open Access Rheumatol 2020;12:87-9.
  23. Cai Z, Zuo R, Liu Y. Characteristics of Kawasaki disease in older children. Clin Pediatr (Phila) 2011;50(10):952-6.
  24. Jindal AK, Pilania RK, Guleria S, Vignesh P, Suri D, Gupta A, et al. Kawasaki Disease in Children Older Than 10 Years: A Clinical Experience From Northwest India. Front Pediatr 2020;8:24.
  25. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004 110(17):2747-71.
  26. Muniz JC, Dummer K, Gauvreau K, Colan SD, Fulton DR, Newburger JW. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging 2013;6(2):239-44.
  27. Wu L, Chen Y, Zhong S, Li Y, Dai X, Di Y. Blood N-terminal Pro-brain Natriuretic Peptide and Interleukin-17 for Distinguishing Incomplete Kawasaki Disease from Infectious Diseases. Indian Pediatr 2015 52(6):477-80.
  28. Nozaki T, Morita Y, Hasegawa D, Makidono A, Yoshimoto Y, Starkey J, et al. Cervical ultrasound and computed tomography of Kawasaki disease: Comparison with lymphadenitis. Pediatr Int 2016; 58(11):1146-52.
  29. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome. N Engl J Med 1991;324(23):1633-9.
  30. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315(6):341-7.
  31. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131(6):888-93.
  32. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2(8411):1055-8.
  33. Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006(4):Cd004175.
  34. Crayne CB, Mitchell C, Beukelman T. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. Pediatr Rheumatol Online J 2019;17(1):77.
  35. Portman MA, Dahdah NS, Slee AS, Olson AK, Choueiter NF, Soriano BD, et al. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics 2019;143(6):e20183675.
  36. Burgner DP, Newburger JW. Etanercept as Adjunctive Primary Therapy in Kawasaki Disease. Pediatrics 2019;143(6).
  37. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31(4):808-10.
  38. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010;157(6):960-966.e1.
  39. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008. 153(6):833-8.
  40. Walser M, Hermann M, Hufnagel M, Haas NA, Fischer M, et al. Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease. Pediatr Infect Dis J 2020.
  41. Tanoshima R, Hashimoto R, Suzuki T, Ishiguro A, Kobayashi T. Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review. Eur J Pediatr 2019;178(6):947-55.
  42. Ouldali N, Pouletty M, Mariani P, Beyler C, Blachier A, Bonacorsi S, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health 2020;4(9):662-8.
  43. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395(10237):1607-8.
  44. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet, 2020. 395(10239):1771-1778.
  45. Colmenero I, Santonja C, Alonso-Riaño M, Noguera-Morel L, Hernández-Martín A, Andina D, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases. Brit J Dermatol 2020.
  46. Berthelot JM, Drouet L, Lioté F. Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? Emerg Microbes Infect 2020;9(1):1514-22.
  47. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020;382(17):1663-5.
  48. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020;145(6):e20200702.
  49. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr 2020. Epub ahead of print.
  50. Parri N, Lenge M. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med 2020;383(2):187-90.
  51. Network CHA. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). 2020. Retrieved from https://emergency.cdc.gov/han/2020/han00432.asp
  52. CDC, Toxic Shock Syndrome (Other Than Streptococcal) (TSS), 2011 Case Definition. Retrieved from https://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/
  53. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020;383(4):347-58.
  54. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020;383(4):334-46.
  55. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020;79(8):999-1006.
  56. Ramcharan T, Nolan O, Lai CY, Prabhu N, Krishnamurthy R, Richter AG, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol 2020;1-11.
  57. Health, R.C.o.P.a.C., Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (1 MAY 2020). 2020. Retrieved from https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims
  58. Alunno A, Carubbi F. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. RMD Open 2020;6(1).
  59. Lee PY, Day-Lewis M, Henderson LA, Friedman K, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 2020. Epub ahead of print.
  60. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2016;68(3):566-76.
  61. Riollano-Cruz M, Akkoyun E, Briceno-Brito E, Kowalsky S, Posada R, Sordillo EM, et al. Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience. J Med Virol 2020. Epub ahead of print.
  62. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020;369:m2094.
  63. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020. Epub ahead of print.